DelveInsight’s, “Ischemic Stroke Pipeline Insight 2023” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Ischemic Stroke pipeline landscape. It covers the Ischemic Stroke pipeline drug profiles, including Ischemic Stroke clinical trials and nonclinical stage products. It also covers the Ischemic Stroke therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the Ischemic Stroke Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Ischemic Stroke NDA approvals (if any), and product development activities comprising the technology, Ischemic Stroke collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

To explore more information on the latest breakthroughs in the Ischemic Stroke Pipeline treatment landscape of the report, click here @ Ischemic Stroke Pipeline Outlook

 

Key Takeaways from the Ischemic Stroke Pipeline Report

• DelveInsight’s Ischemic Stroke Pipeline analysis depicts a robust space with 50+ active players working to develop 55+ pipeline treatment therapies.
• The leading Ischemic Stroke Companies are working in the market include Genentech, Supergene, Tasly Pharmaceutical, Pharmazz, GNT Pharma, NoNO, Angde Biotech Pharmaceutical, ZZ Biotech, Bristol-Myers Squibb, Athersys, Bayer Healthcare, NuvOx Pharma, Healios, Acticor Biotech, DiaMedica Therapeutics, Moleac, Biogen, Revalesio Corporation, Shijiazhuang Yiling Pharmaceutical Co. Ltd, and others.
• Promising Ischemic Stroke Pipeline therapies in the various stages of development include SB623 Implant (2.5M), SB623 Implant (5.0M), Solitaire, Cerebrolysin, 0.9% Saline Solution, YM872 (zonampanel), t-PA (alteplase), UMC119-06, JTR-161, Tirofiban 0.05 MG/ML, 0.9% sodium chloride solution, Neurothrombectomy, and others
• On February 2023, GrandPharma Co Ltd has announced drug named Tirofiban 0.05 MG/ML and 0.9% sodium chloride solution by the phase 2. The study is a prospective, multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of tirofiban in combination with intravenous thrombolytic therapy with alteplase in acute ischemic stroke.

 

Ischemic Stroke Overview

Stroke is a leading cause of death and disability worldwide and can be broadly classified into ischaemic stroke and haemorrhagic stroke, the latter of which includes intracerebral haemorrhage and subarachnoid haemorrhage. Ischaemic stroke is defined as infarction of the brain, spinal cord or retina1 and represents ~71% of all strokes globally.

 

For further information, refer to the detailed Ischemic Stroke Unmet Needs, Ischemic Stroke Market Drivers, and Market Barriers, click here for Ischemic Stroke Ongoing Clinical Trial Analysis

 

Ischemic Stroke Emerging Drugs Profile

• 3K3A-APC: ZZ Biotech
• BMS-986177: Bristol-Myers Squibb
• XY03 EA: Shijiazhuang Yiling Pharmaceutical Co. Ltd.
• NONO-42: NoNO Inc.

 

Ischemic Stroke Pipeline Therapeutics Assessment

There are approx. 50+ Ischemic Stroke companies which are developing the therapies for Ischemic Stroke. The Ischemic Stroke companies which have their Ischemic Stroke drug candidates in the most advanced stage, i.e. phase III include, ZZ Biotech.

 

Request a sample and discover the recent advances in Ischemic Stroke Ongoing Clinical Trial Analysis and Medications, click here @ Ischemic Stroke Treatment Landscape

 

Ischemic Stroke Therapeutics Assessment

• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

 

Some of the Companies in the Ischemic Stroke Therapeutics Market include-

Genentech, Supergene, Tasly Pharmaceutical, Pharmazz, GNT Pharma, NoNO, Angde Biotech Pharmaceutical, ZZ Biotech, Bristol-Myers Squibb, Athersys, Bayer Healthcare, NuvOx Pharma, Healios, Acticor Biotech, DiaMedica Therapeutics, Moleac, Biogen, Revalesio Corporation, Shijiazhuang Yiling Pharmaceutical Co. Ltd, and others.

 

Dive deep into rich insights for drugs for Ischemic Stroke Pipeline, click here @ Ischemic Stroke Unmet Needs and Analyst Views

 

Scope of the Ischemic Stroke Pipeline Report

• Coverage- Global
• Ischemic Stroke Companies- Genentech, Supergene, Tasly Pharmaceutical, Pharmazz, GNT Pharma, NoNO, Angde Biotech Pharmaceutical, ZZ Biotech, Bristol-Myers Squibb, Athersys, Bayer Healthcare, NuvOx Pharma, Healios, Acticor Biotech, DiaMedica Therapeutics, Moleac, Biogen, Revalesio Corporation, Shijiazhuang Yiling Pharmaceutical Co. Ltd, and others.
• Ischemic Stroke Therapies- include SB623 Implant (2.5M), SB623 Implant (5.0M), Solitaire, Cerebrolysin, 0.9% Saline Solution, YM872 (zonampanel), t-PA (alteplase), UMC119-06, JTR-161, Tirofiban 0.05 MG/ML, 0.9% sodium chloride solution, Neurothrombectomy, and others.
• Ischemic Stroke Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Ischemic Stroke Merger and acquisitions, N Ischemic Stroke Licensing Activities @ Ischemic Stroke Emerging Drugs, and Recent Trends

 

Table of Content

1. Introduction
2. Executive Summary
3. Ischemic Stroke: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Ischemic Stroke– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. 3K3A-APC: ZZ Biotech
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. XY03 EA: Shijiazhuang Yiling Pharmaceutical Co. Ltd.
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. NONO-42: NoNO Inc.
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Ischemic Stroke Key Companies
21. Ischemic Stroke Key Products
22. Ischemic Stroke- Unmet Needs
23. Ischemic Stroke- Market Drivers and Barriers
24. Ischemic Stroke- Future Perspectives and Conclusion
25. Ischemic Stroke Analyst Views
26. Ischemic Stroke Key Companies
27. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services